Brainstorm recruits Novartis vet Araya as chief commercial officer; Roche out-licenses IPF drug to Shanghai's Ark
→ BrainStorm Cell Therapeutics $BCLI has appointed Novartis vet Arturo Araya as chief commercial officer. Araya had been global head of commercial of Novartis’ Cell and Gene Therapies Unit and has been on the board at Brainstorm since February of last year.
→ Roche struck a deal to out-license an IPF drug to Shanghai-based Ark Biosciences, helmed by CEO Jim Wu. The biotech got the global rights to the drug, which has been through the first round of human studies. The statement did not include any details on the financing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
